Gilead Sciences

Gilead Sciences, Inc. is one of the world’s leading biopharmaceutical companies focused on discovering, developing, and delivering innovative medicines for life-threatening diseases. Established in 1987 and headquartered in Foster City, California, USA, the company has built a global reputation for advancing treatments in virology, oncology, inflammatory diseases, and cell therapy. Gilead is particularly recognized for its groundbreaking work in HIV treatment, hepatitis B and C therapies, COVID-19 antiviral research, and innovative cancer treatments.

The company combines advanced biotechnology, medicinal chemistry, genomics, and data-driven research to develop therapies that address significant unmet medical needs. Through strategic acquisitions and collaborations, Gilead has expanded its capabilities in oncology, immunology, and cell therapy, strengthening its global research and development pipeline. Its products are available in more than 100 countries, supported by an extensive manufacturing and commercial network.

Gilead is committed to maintaining high standards of quality, regulatory compliance, environmental responsibility, and corporate ethics. The company invests substantially in scientific innovation, clinical trials, patient access programs, and partnerships with healthcare organizations worldwide. With a strong emphasis on improving global health outcomes and accelerating medical breakthroughs, Gilead continues to be one of the most influential biotechnology companies, delivering innovative therapies that have transformed the treatment of infectious diseases and cancer for millions of patients worldwide.